The goal of this K24 Mid-Career Clinician-Scientist proposal is to allow the Candidate, Dr. Edward Nunes, to continue to expand his program of research and research mentorship in the field of drug abuse treatment development. The Candidate's research program focuses on two related themes, the treatment of co-occurring psychopathology in substance dependent patients, and the development of combinations of behavioral and pharmacological treatments for drug dependence. Major activities and accomplishments have included a series of studies examining the efficacy of antidepressant medications for treatment of opioid, cocaine, and alcohol dependent patients with depression, projects applying advances in behavioral therapies to naltrexone maintenance for opioid dependence and to treatment of depression among methadone maintained patients, applications of behavioral therapy to enhance the design of cocaine medications development trials, and multi-site effectiveness trials in the NIDA Clinical Trials Network. Through collaborations and the work of colleagues Dr. Nunes has, and continues to mentor, his agenda has expanded to examine structured psychiatric diagnostic methods, HIV risk reduction, and other co-occurring psychopathology including attention deficit hyperactivity disorder, impulsive aggression, post-traumatic stress disorder, pathological gambling, neuropsychological functioning, and childhood psychopathology and risk for drug dependence. Over the course of the proposed K24 Dr. Nunes will serve as Principle Investigator on a Center Project, two R01s, and the Long Island Node of the Clinical Trials Network, and as Co-l, Sponsor, or Co-Sponsor on funded projects of junior colleagues and mentored K awards. In particular the K24 will free Dr. Nunes'time and provide resources to pursue the development of new initiatives and collaborations in treatment research and to create opportunities in patient-oriented research for junior colleagues. The mentoring plan will serve young investigators at three main levels, 1) junior faculty with early or emerging independent research programs many of whom Dr. Nunes has mentored since fellowship or during K awards, 2) three current K23 awardees for whom Dr. Nunes serves as Sponsor, and three current (or anticipated) K23 or K01 awardees for whom he serves as Co-Sponsor or Consultant, and 3) Post doctoral fellows in clinical research in the Department's NIDA funded T32 research fellowship program. In addition Dr. Nunes will seek to foster independent research initiatives and collaborations involving the clinical leadership of community-based treatment programs participating in the Clinical Trials Network. The ultimate goals are to improve the treatment of drug dependent patients through clinical research and to help foster the next generation of clinician-researchers.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
Application #
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Aklin, Will
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code
Mariani, John J; Malcolm, Robert J; Mamczur, Agnieszka K et al. (2016) Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. Am J Drug Alcohol Abuse 42:333-40
Lee, Joshua D; Friedmann, Peter D; Kinlock, Timothy W et al. (2016) Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med 374:1232-42
Murphy, Sean M; Campbell, Aimee N C; Ghitza, Udi E et al. (2016) Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial. Drug Alcohol Depend 161:119-26
Carpenter, Kenneth M; Amrhein, Paul C; Bold, Krysten W et al. (2016) Derived relations moderate the association between changes in the strength of commitment language and cocaine treatment response. Exp Clin Psychopharmacol 24:77-89
Bedi, Gillinder; Shiffrin, Laura; Vadhan, Nehal P et al. (2016) Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers. J Psychopharmacol 30:370-7
Sanchez, Katherine; Walker, Robrina; Campbell, Aimee N C et al. (2015) Depressive Symptoms and Associated Clinical Characteristics in Outpatients Seeking Community-Based Treatment for Alcohol and Drug Problems. Subst Abus 36:297-303
Sullivan, Maria A; Bisaga, Adam; Glass, Andrew et al. (2015) Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug Alcohol Depend 147:122-9
Wain, R Morgan; Kutner, Bryan A; Smith, Jennifer L et al. (2015) Self-Report After Randomly Assigned Supervision Does not Predict Ability to Practice Motivational Interviewing. J Subst Abuse Treat 57:96-101
Cochran, Gerald; Stitzer, Maxine; Campbell, Aimee N C et al. (2015) Web-based treatment for substance use disorders: differential effects by primary substance. Addict Behav 45:191-4
Grant, Bridget F; Goldstein, Rise B; Smith, Sharon M et al. (2015) The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): reliability of substance use and psychiatric disorder modules in a general population sample. Drug Alcohol Depend 148:27-33

Showing the most recent 10 out of 94 publications